Navigation Links
ThromboGenics and BioInvent Complete Patient Recruitment of Phase II DVT Prophylaxis Study With Anti-Factor VIII (TB-402)
Date:10/28/2009

LEUVEN, Belgium and LUND, Sweden, October 28 /PRNewswire-FirstCall/ --

- Recruitment of 315 Patients Completed Ahead of Schedule - Results Anticipated in the second quarter of 2010

ThromboGenics NV (Euronext Brussels: THR) and co-development partner BioInvent International (OMXS: BINV) announce that they have completed recruitment of their Phase II trial of TB-402 ahead of schedule. TB-402 is a novel, long acting anticoagulant that is being developed for the prevention of deep vein thrombosis (DVT) following orthopaedic surgery. The results of this study, which has recruited 315 patients, are anticipated in the second quarter of 2010.

TB-402 has the potential to be a very important new entrant into the anticoagulant market. TB-402 is a recombinant human monoclonal antibody that partially inhibits Factor VIII, a key component of the coagulation cascade. This novel mode of action is expected to reduce the risk of undesirable bleeding events, even at high doses, as well as the need for patient monitoring. These are the two main drawbacks associated with current anticoagulant therapy. In addition, TB-402 is a long-acting agent, which means it could be given as a single dose to prevent the development of DVT in patients undergoing surgery. This would be an attractive option, as all current anticoagulant treatment options require daily treatment for up to several weeks.

The Phase II trial is an active (enoxaparin)-controlled, dose-escalating, multicenter, prospective, randomised, open label trial evaluating TB-402 for the prophylaxis of DVT after knee surgery. The study is assessing three different doses of TB-402 (0.3, 0.6 and 1.2 mg/kg) each given as a single intravenous bolus injection post knee replacement surgery. The objective of the study is to assess the safety and efficacy of the three escalating doses of TB-402. The study enrolled a total of 315 patients across 30 centers, mainly in Eur
'/>"/>

SOURCE ThromboGenics NV
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. ThromboGenics Completes Patient Enrolment in US Phase III Trial of Microplasmin for the Non-Surgical Treatment of Eye Disease
2. ThromboGenics and BioInvent Start Recruitment of Second 100 Patient Cohort in Phase II DVT Prophylaxis Study With TB-402
3. ThromboGenics Microplasmin Phase III Program Progressing According to Schedule
4. ThromboGenics Completes Patient Enrolment for Phase II Trial of Microplasmin for the Treatment of Diabetic Macular Edema (MIVI II DME)
5. ThromboGenics and BioInvent Receive Technology Transfer Success Fee From Roche for the Novel Anti-Cancer Antibody, TB-403 (Anti-PIGF)
6. ThromboGenics Begins Phase III Program With Microplasmin for the Non-surgical Treatment of Back of the Eye Disease
7. ThromboGenics Announces Promising Results of MITI IV Phase II Trial in the Treatment of Acute Stroke with Microplasmin
8. ThromboGenics Completes Patient Enrolment in the Phase IIb Trial of Microplasmin in Vitrectomy (MIVI III)
9. Elekta Provides Complete Planning, Treatment and Workflow Solution for Roy and Patricia Disney Family Cancer Center
10. Delcath Systems, Inc. Completes Phase III Study Enrollment
11. Abbott Completes Visiogen Acquisition
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/22/2014)... 22, 2014  ConvaTec, a privately-held medical products and ... has been appointed chief financial officer of the company, ... previously executive vice president and chief financial officer of ... company.  Mr. Clerkin was part of a senior team ... in its sale to Perrigo, a pharmaceutical manufacturer, in ...
(Date:7/22/2014)... ST. LOUIS , July 22, 2014  According ... the time their children spend on digital devices. An ... the ages of 10 and 17 estimate they use ... day. However, a separate AOA survey of parents revealed ... use an electronic device for that same amount of ...
(Date:7/22/2014)... LOS ANGELES , July 22, 2014  NeuroSigma, ... sciences company focused on commercialization of its non-invasive ... of neurological and neuropsychiatric disorders, today announced that enrollment ... external trigeminal nerve stimulation (eTNS) as adjunctive therapy for ... trial is being conducted at the Olive View-UCLA Medical ...
Breaking Medicine Technology:ConvaTec Names Nigel Clerkin Chief Financial Officer 2Survey Reveals Parents Drastically Underestimate the Time Kids Spend on Electronic Devices 2Survey Reveals Parents Drastically Underestimate the Time Kids Spend on Electronic Devices 3Survey Reveals Parents Drastically Underestimate the Time Kids Spend on Electronic Devices 4Enrollment Commences in NeuroSigma-Sponsored Pediatric Clinical Trial for the Treatment of Lennox-Gastaut Syndrome 2Enrollment Commences in NeuroSigma-Sponsored Pediatric Clinical Trial for the Treatment of Lennox-Gastaut Syndrome 3Enrollment Commences in NeuroSigma-Sponsored Pediatric Clinical Trial for the Treatment of Lennox-Gastaut Syndrome 4Enrollment Commences in NeuroSigma-Sponsored Pediatric Clinical Trial for the Treatment of Lennox-Gastaut Syndrome 5
(Date:7/22/2014)... July 22, 2014 Get Real ... Immune Deficiency Foundation (IDF) to provide their ... that will allow them to electronically track their symptoms, ... their illnesses. It will also allow those patients and ... consent to have their data shared with the ...
(Date:7/22/2014)... 22, 2014 JumpSoft, Inc., a ... automated recovery at the application level, today released ... to application-centric management. , Based on ... the report provides insights, context and depth regarding ... application and system uptime. London, Ink, a B2B ...
(Date:7/22/2014)... Recently, MyDressCity.com has excitedly launched a promotion for ... all people can get a discount, up to 60% off, ... the new range; all the new items are of top ... Quinceanera gowns for worldwide clients. Our dress specialists are always ... of MyDressCity.com, “Our Quinceanera dresses are selling well in the ...
(Date:7/22/2014)... July 22, 2014 BlackBox Biometrics, Inc. ... Gauge™ System with advancements including a new ... gauges represent a functional revision of the already robust ... capture complex data on blast events by recording a ... The extreme changes in overpressure that accompany a blast ...
(Date:7/22/2014)... (PRWEB) July 22, 2014 "The Big Secrets: ... is one of the most important books young people can read. ... It will murder some of the “truths” people have been living ... what will the new truths be? From sex to death, this ... age 16 to 21, and it tells it like it is. ...
Breaking Medicine News(10 mins):Health News:Get Real Health to Partner with Immune Deficiency Foundation 2Health News:Get Real Health to Partner with Immune Deficiency Foundation 3Health News:JumpSoft Releases Report on Shift from Infrastructure-Centric to Application-Centric IT Management 2Health News:JumpSoft Releases Report on Shift from Infrastructure-Centric to Application-Centric IT Management 3Health News:Beautiful Dama Dresses Now Released By Popular Online Supplier MyDressCity.com 2Health News:BlackBox Biometrics®, Inc. continues to advance blast overpressure measurement with release of new Blast Gauge 2Health News:BlackBox Biometrics®, Inc. continues to advance blast overpressure measurement with release of new Blast Gauge 3Health News:Strategic Book Publishing & Rights Agency Announces the Release of its Newest Title, “The Big Secrets: Ten Things Every Young Person Should Know About and Why” 2
... number of HIV cases in Africa as of last ... from the United Nations //.The World Health Organization has ... AIDS in Africa. ,The WHO has ... in healthcare in Africa could be used to give ...
... Science (RIMS) here is battling for life after doctors gave her ... to RIMS for a surgery, received B+ blood instead of her ... next 48 hours are critical for her. ,She was ... ago. Her condition worsened when she was given the wrong blood, ...
... replaced by a pill according to European researchers. The ... of the Grazax allergen tablet.// Hay fever and other ... ,Allergies are a result of the immune system reacting ... ,Immunotherapy is supposed to enhance tolerance of ...
... of people admitted into hospitals with diabetic related issues is ... of Health and Welfare.// ,The author of the report, ... and 2004, hospital admissions for diabetes increased by 20 per ... more people are being diagnosed with diabetes, it is increasing ...
... have found that a glass of orange juice every day ... citrus juices like lemonade. // ,The study that is ... 26 issue of the Clinical Journal of the American Society ... that all citrus fruit juices could help prevent the formation ...
... Australia are conducting a study involving 300 pairs of older ... ,'Even though we have twins that are identical, ... Sachdev said. 'By studying twins, we will be able to ... and which are environmental.' ,Prof Sachdev said that time ...
Cached Medicine News:Health News:A Glass of Orange Juice To Keep Recurrence Of Kidney Stones At Bay 2
Form should always follow function. Thats why EagleVision created the FlexPlug, the only tapered shaft punctum plug with contouring traction ribs. Designed to provide the ultimate in flexibility, fix...
The latest wave in punctum plugs! Unique design featureing reservoir indentations to reduce foreign body sensation. Elast™ - a proprietary formulated, hight performance Liquid Silicon Rubber ...
... Attain Prevail's steerable tip, along with various ... obtain the curve you need, when you ... visualization of the cardiac venous anatomy, adjust ... - Adjust curve and reach by ...
... Attain™ Deflectable Catheter - designed to be ... single catheter. Steerablility - Create a variety ... a single, steerable guide catheter. Lock the ... to address each patient's unique anatomy during ...
Medicine Products: